The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.
Male or female at least 18 years old;
diagnosed with AS according to the 1984 New York Modified Criteria;
Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;
BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;
With unstable vital signs, coma, mental and cognitive impairment;
Patients with severe systemic diseases and other serious chronic diseases;
Pregnant or lactating patients;
History of malignant tumor in the past 5 years;